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Objectives: To explore the Four Rs of Radiobiology (Repair, Reoxygenation, Reassortment and 
Repopulation) as a means to understand the effects of ionising radiation on biological tissue and 
subsequently as the basis for conventional fractionated treatment schedules. These radiobiological 
principles will form a rationale for combined regimens in prostate cancer (PCa) treatment involving 
Androgen Deprivation Therapy (ADT) and Radiation Therapy (RT) and the associated toxicities of this 
approach will be discussed.   
 
Data Sources:  Electronic databases including CINAHL, MEDLINE, Scopus, professional websites, 
books and grey literature were searched using Google scholar. 
 
Conclusion: It is important for nurses to understand the Four Rs of Radiobiology to grasp the effects 
of ionising radiation on biological tissue as the basis for conventional fractionated treatment 
schedules in PCa. Men can experience a sequalae of physical and psychological side-effects of 
treatment which can negatively impact quality of life. 
 
Implications for Nursing Practice: Men can experience a range of unmet supportive care needs 
particularly related to informational, sexual and psychological needs.  For men affected by PCa opting 
for RT (+/-) ADT nurses should ask targeted questions based on the Common Terminology Criteria for 
Adverse Events (CTCAE) related to urinary and bowel function, potency and fatigue and sexual 
health.  We also recommend the use of holistic needs assessments to tailor self-management care 
plans.  Evidence-based self-management advice should be provided in response to each man’s 
unique needs.      
 
Keywords: Radiobiology; 4Rs, Prostate Cancer; Androgen Deprivation Therapy; Toxicities; Specialist 
Nursing  
Introduction 
The biological effect that ionising radiation has on both normal and tumour tissue can be understood 
through the exploration of four radiobiological principles (4R’s): Repair of sublethal damage, 
Reoxygenation, Reassortment and Repopulation. The Radiosensitivity of specific cells is also 
pertinent to the process (this is sometimes referred to as the fifth ‘R’) however, it is inextricably 
linked to Repair [1]. These principles are used to justify dose fractionation in radiation treatment [2]. 
When a treatment dose is divided into fractions and enough time is provided between doses, normal 
tissues have the ability to recover through repair and repopulation of cells into the tissues, and the 
tumour itself is adversely affected by the reoxygenation and reassortment of cells [3].  
Understanding this interaction between ionising radiation and tumour tissues can allow the 
microenvironment, in more radioresistant cells, to be manipulated and sensitised by the introduction 
of adjuvant therapies [4, 5]. The combined use of ADT with RT in the treatment of PCa, is an example 
of this symbiotic relationship, noting that an improvement in overall survival is observed with 
traditional treatment modalities, compared with RT alone [6-9]. However, given the myriad of 
potential side effects that accompany ADT, alongside the technological advances in contemporary RT 
that permit larger doses to the tumour bed with greater precision, clinical trials are underway to 
assess the continued efficacy of a multimodal approach at higher RT doses [10, 11]. Although, these 
trials are yet to divulge conclusive findings and therefore (neo)adjuvant interventions remain 
standard practice for particular biochemical disease manifestations [12]. Duration and timing of ADT 
are also variables that have warranted investigation, with the intent to strike an optimal balance 
between oncological benefit and toxicity related quality of life (QoL) considerations [4].  
 
Therefore, this article will provide an overview of the concept of the 4R’s of radiobiology and 





Repair of Sublethal Damage 
 
Ionising radiation can cause a cascade of events within a cell that will ultimately lead to a transient or 
permanent alteration [13]. The most important target within that cell is the DNA, as it contains the 
genetic information required to maintain cell survival and function. Damage to the DNA may lead to 
either cell malfunction or cell death and this can occur when radiation acts directly on the DNA or 
indirectly by acting elsewhere in the cell, particularly on water molecules in the presence of oxygen. 
This induces the formation of free radicals, which are highly reactive and will combine with other 
atoms to cause chemical change and damage within a cell [14]. Damage to the DNA can either result 
in a single strand break, which is easily rectified or a double strand brand break, which results in cell 
death or permanent alterations (when the chromosomes re-join incorrectly) if the repair processes 
are not sufficient [3]. Cell kill from ionising radiation occurs through the generation of unrepairable 
lesions involving DNA double strand breaks [15]. The majority of DNA damage is sublethal and has 
the capacity for repair within hours unless additional sublethal damage occurs [3]. Sublethal damage 
repair conceptualises the idea that cell killing is reduced if a dose of radiation is delivered in two or 
more fractions with a given time interval [14]. Repair of sublethal damage is nutrient and oxygen 
dependent and because the majority of tumour cells are thought to have a hypoxic component, they 
are considered less effective at carrying out the repair process than normal tissues [16]. The rate of 
repair and the inherent cellular radiosensitivity will have significant bearing on the response to 
radiation and consequently the overall ability to eradicate tumour cells, thereby reducing the 
incidence of recurrence and relapse [17]. This is clinically significant as the tissue’s radiosensitivity 
and capacity for repair inform the prescribed dose fractionation and interfraction interval to allow 
normal tissues to repair [1] while preventing the possibility of chromosomal aberrations, which could 





The efficacy of radiation can be linked to the availability of oxygen within the target tissue. Blood 
supply to a tissue is a major determinant in the amount of available oxygen. Normal tissues have an 
adequate supply to all areas through a network of capillaries however, tumours tend to outgrow 
their blood supply leading to areas of hypoxia [14]. The hypoxic regions can be found throughout the 
tumour and can drastically affect the cytotoxicity of radiation and therefore impede its success [2]. 
The oxygen saturation of cells is dynamic, and tumours can be both acutely and chronically hypoxic  
[18]. Acute hypoxia occurs when there is an intermittent and temporary closure of the supplying 
blood vessels and chronic hypoxia occurs when cells are not close enough to the blood supply to 
allow diffusion of oxygen to take place [15]. Hypoxic cells gain access to oxygen through a process of 
reoxygenation. Providing sufficient time is allocated between radiation doses a proportion of cells 
will have time to reoxygenate and become more sensitive to the next treatment [16]. The biological 
and radiation response of the cells is directly affected by the extent of the hypoxic conditions and the 
amount of time spent in the hypoxic state. Cells that are irradiated shortly following the 
reoxygenation process have a higher radiosensitivity than those irradiated after being in hypoxic 
conditions for up to 24 hours [15]. Reoxygenation of hypoxic cells is possible and particularly 
effective when dose fractionation is employed. This is due to the likelihood of the first dose fraction 
killing a large proportion of the well oxygenated and radiosensitive cells located near the tumours 
blood supply [16]. Following irradiation, a large fraction of cells become hypoxic however, this is 
short lived as the tumour returns to its original proportions of oxygenated and hypoxic cells [19]. As 
the dead cells are broken down and removed, the tumour shrinks and undergoes revascularisation 
and restructuring, so that those surviving hypoxic cells now have access to a blood supply and are 
able to reoxygenate. These newly reoxygenated cells are now more sensitive to the next dose 
fraction of radiation [3] , see Figure 1. 
Reassortment 
 
Reassortment or redistribution recognises that cells exhibit differential radiation sensitivity during 
different phases of the cell cycle [15]. The cell cycle can be divided into four separate and distinctive 
phases, see Figure 2: 
 G1 – The cells are preparing for replication. 
 S – Is the stage where the DNA is replicated or synthesised 
 G2 – The cells are preparing for division 
 Mitosis (M) – The chromosomes condense and divide to produce identical daughter cells [2]. 
 
If a cell moves out of the active cell cycle and rests (does not divide) it is considered to be in the G0 
phase. Cells can also leave G0 and move back into the active cycle to increase cells numbers. Prior to 
irradiation a population of cells will tend to show an asynchronous distribution, that is, the cells will 
be dispersed throughout all phases of the cell cycle [16]. Those cells that are located in the Mitosis 
and G2 phases will be more sensitive to radiation induced killing, whereas those cells moving through 
the S phase (particularly the late S phase) will be the most radioresistant [20]. Following irradiation, 
cells that were once randomly distributed will synchronise, as those that were located in the 
sensitive stages have been killed off leaving only those in the more resistant phase. Clinically, an ideal 
situation exists when radiation treatment can be timed to target tumour cells as they move into the 
sensitive phase of the cell cycle, preserving normal cells that have moved into the resistant phase  
[16]. Redistribution into the sensitive phases of the cycle is dependent on the ability of the cells to 
proliferate. The normal non-proliferating tissues such as the spinal cord and connective tissue may 
not be affected while those tissues experiencing rapid proliferation, such as tumours can be more 
sensitised to redistribution [21]. Variation in cell sensitivity is an important consideration for the 
delivery of radiation treatment. Delivery of ionising radiation in fractionated doses improves the 
probability that tumour cells will be in the sensitive phase of the cell cycle at some point during the 
treatment regime resulting in increased tumour cell kill [3]. 
Repopulation 
 
As previously established, not all cells are active within the cell cycle. Those that are ‘resting’ (those 
located in G0) can enter the cell cycle at any stage to replace the cells that have incurred radiation 
damage and been destroyed [14]. The clonogens (surviving cells) in the surrounding tissue or the 
tumour itself commence cell division and partially or completely repopulate the area [16]. 
Repopulation can occur through either cell proliferation or cell immigration. Cell proliferation occurs 
in tissues with a rapid rate of cell production and those that can meet demand by speeding up cell 
production (such as skin). Cell migration involves stem cells moving into the necessary location and 
differentiating to perform the desired functions [21]. The microenvironments role in driving 
repopulation is dependent on an individual’s immune status, tumour type and planned radiation 
schedule [22]. It is highly beneficial for normal tissues to repopulate, as this can minimise the 
accumulative long-term effect that radiation can have on tissues with low proliferation rates. 
However, repopulation of tumour cells is highly disadvantageous to the radiation therapy treatment 
process [16]. As radiation is a cytotoxic treatment agent it can actually promote cell division to occur 
at a higher rate, this is termed accelerated repopulation [3]. Accelerated repopulation is detrimental 
to the cure rate of malignant cells unless the treatment doses match the rate of cell production [14]. 
Given inter-tumour variability can be substantial, a balance of time is essential in Radiation Therapy 
to counteract the effects of repopulation within a tumour [19]. If the treatment period exceeds a 
certain amount of time, approximately 28 days (which is when the cells will commence repopulation) 
then a daily compensational dose increment is necessary, otherwise the overall effectiveness of 
treatment will be reduced [3]. Fractionated doses are a means of sparing normal tissues within the 
treatment field and accelerated treatment regimens can be developed to deliver the total dose 
within a shorter time frame to compensate for repopulation [14].   
 
Combined Treatments in Prostate Cancer 
 
Biological Basis for Combined Treatment  
 
Androgens are a group of male sex hormones that are synthesised in the adrenal glands and 
interstitial cells of the testes. They are responsible for sexual and reproductive function in men, with 
gonadal testosterone comprising the main source of circulating androgens [23, 24]. Both normal and 
abnormal (cancerous) cells in the prostate gland rely on testosterone to grow [25] and because PCa is 
susceptible to androgens, rendering it a hormone-sensitive disease, it has been identified to 
significantly benefit from ADT, which can be implemented at various points throughout the PCa 
treatment trajectory [26]. Typically, PCa cells are considered radioresistant, as testosterone activates 
androgen receptors (AR) and in turn stimulates the DNA repair pathways that would have otherwise 
been damaged when interacting with ionising radiation. It is the AR signalling that encourages the 
continued growth and survival of the tumour cells [4, 24, 27]. The tumours dependence on AR 
activity can be manipulated when hormone therapy is used as an adjunct to the radiation regimen. 
ADT can alter the tumour microenvironment by inhibiting cell repopulation and proliferation and 
deactivating the DNA repair machinery leaving the cells more sensitive to radiation [5]. It is also 
postulated that ADT can improve PCa cell re-oxygenation, normalise the vasculature and 
consequently enhance tissue perfusion. All of which increase the likelihood of radiation induced cell 
kill, without compromising the integrity of the normal surrounding tissues [4, 5]. 
Supporting Evidence for Combined Treatment  
 
Evidence underscores that using ADT in combination with RT can improve local tumour control and 
mitigate the risk of distant metastasis, thereby impacting on long-term disease free survival for those 
patients with locally advanced and high risk disease [4, 28], see Table 1 and Table 2 for diagnostic 
classifications. The European Organisation for Research and Treatment of Cancer (EORTC) conducted 
a phase III trial comprising 415 patients, with high risk localised or locally advanced disease, who 
were randomised to RT (70Gy) with or without long term (3 years) adjuvant ADT. The overall survival 
at 5 years was 78% for combined treatment and 62% for RT alone. EORTC also established that those 
surviving at 5 years had a disease free rate of 74% for the combined treatment compared with 40% 
for RT alone [29, 30]. The 10-year results of this trial maintained superior outcomes for combined 
treatment across multiple domains, with 58.1% overall survival recorded compared with 39.8% in RT 
alone. Locoregional failure rate was significantly reduced for the combined approach compared with 
RT alone, reporting 6.0% and 23.5% respectively. The combined treatment group demonstrated 51% 
distant metastasis free survival versus 30.2% for RT and finally there was a statistically significant 
reduction in prostate cancer mortality at 10 years with 10.3% mortality rate for combined group as 
opposed to 30.4% for the single treatment RT group [31]. 
 
These findings were confirmed by Mason et al who conducted a large intergroup study to determine 
whether overall survival would benefit from the addition of RT to ADT. 1,205 men were randomly 
assigned to lifelong ADT alone or to a combination of ADT and RT (64-69Gy). With a median follow up 
of 8 years, an improvement was documented in both prostate specific and overall survival outcomes 
for those partaking in combined therapy. ADT and RT together resulted in a significant reduction in 
prostate cancer related death (P < 0.001) and the overall risk of death had reduced by 30%. The 10 
year overall survival rate was 55% for those undergoing ADT and RT compared with 49% for those 
receiving ADT alone [32]. Amit et al [7] posed the question as to whether the addition of ADT was still 
beneficial in men with intermediate risk prostate cancer receiving a higher dose of RT (78-82Gy). The 
results found a beneficial role for the addition of short-term ADT with this particular group however, 
biochemical relapse free survival at 6 year follow up favoured men ≤ 70 years (82.1% for RT alone 
and 94% for combined therapy). Interestingly those patients > 70 years revealed no significant 
difference between treatment groups.  
 
Duration of ADT 
 
The continued advantage of combining ADT with modern (higher) RT doses is an area that has 
sparked considerable debate. Much of the evidence available uses doses far below current standards 
however, a study involving 168 patients with high risk PCa receiving ADT, with the addition of dose 
escalated RT (80Gy), achieved 79% biochemical progression free rate at 5 year follow up [32]. As 
more contemporary results emerge, it has become clear that there are many variables involved in 
changing the landscape of current practice and a consistent thread in the literature is a lack of 
consensus regarding the optimal duration of ADT [6, 33]. Although advances in RT treatment 
planning and delivery may not preclude the need for ADT with intermediate or high risk patients, it 
may provide the option to reduce the duration of hormonal therapy, minimising the prevalence of 
life altering toxicities and allowing earlier testosterone recovery [4]. Bolla et al [34] concluded that 
implementing 6 months of ADT with a RT dose up to 78Gy would be an acceptable compromise 
between disease management and QoL. They reported a statistically significant difference in the 5-
year biochemical disease-free rate between the combined treatment arm (82.6%) and RT alone 
(69.8%). Zapetero et al [11] undertook a phase III trial, which aimed to bridge the gap between 
duration of ADT and contemporary RT treatment modalities. The patients were assigned to either 
short duration ADT, receiving 2 months neoadjuvant therapy and another 2 months combined with 
RT (4 months total) or long-term ADT which continued hormone suppression for a total of 24 
months. Both groups received an isocentre dose of 78Gy to the prostate. The results indicate a clear 
benefit in favour of long-term ADT in combination with high dose RT for those with high risk 
pathology. Disease free survival at 5 years was 90% for those on long term ADT compared to 81% of 
those in the short-term ADT group.  
 
Noteworthy, is the risk of non-compliance for those studies involving long term ADT. The RTOG 8531 
trial revealed that 25% and 68% of patients prescribed lifelong ADT voluntarily ceased treatment at 2 
years and 5 years respectively [9]. A study conducted by Nabid et al [35] noted a compliance rate of 
53% for long term ADT (36 months), in contrast 88% of patients were found to comply with 
intermediate term ADT (18 months). There was also minimal difference in overall survival at a 9.4-
year follow-up for those receiving a shorter duration of ADT. A systematic review identified that the 
evidence supports 24 months of adjuvant ADT with RT however, the findings do not necessitate 
extending treatment beyond that time frame for high risk patients, with consideration given to pre-
existing comorbidities when deciding optimal duration [6].  




While there are many benefits of using ADT in the treatment of PCa, there is a constellation of well-
documented adverse effects than can have a drastic and negative impact on quality of life (QoL) and 
potentially exacerbate pre-existing co-morbidities [7]. The severity of toxicity side-effects of ADT 
include: fatigue, hot flushes, sexual dysfunction (loss of libido and erectile dysfunction), cognitive 
decline, altered body composition (obesity and sarcopenia), atherosclerosis, osteoporosis with 
increased risk of fracture, gynecomastia and metabolic syndrome (elevated triglycerides, increased 
waist circumference and insulin resistance) which may eventuate in new onset diabetes mellitus [27, 
34, 36].  
 
More striking are the implications that androgen suppression may be associated with an increased 
risk of cardiovascular (CV) related events and CV mortality, although this remains somewhat 
controversial. In the earliest study to suggest a link between CV risk and ADT, Keating et al [37] 
undertook a SEER-Medicare review of over 73,000 men with locoregional PCa receiving a 
gonadotropin-releasing hormone (GnRH) agonist and found an increased risk of 16% for coronary 
heart disease, 11% for myocardial infarction (MI) and 16% for sudden cardiac death. Following a 
pooled analysis of men in three randomised trials with varying durations of ADT, D’Amico et al [38] 
noted that men > 65 years receiving 6 months of ADT had shorter times to fatal MI however, this 
may be attributed to pre-existing comorbidities. In a prospective cohort study, Haque et al [39] found 
that men with localised PCa using ADT were at greater risk of certain CV disease outcomes, such as 
heart failure, whereas arrhythmias and conduction disorders were only prevalent in those with pre-
existing CV conditions. The majority of evidence reporting a plausible link derives from large 
observational studies however, contrary to D’Amico’s conclusions, when other randomised trials 
were reanalysed to assess the risk of ADT related CV events between those men receiving or not 
receiving ADT, there was no direct correlation established [40]. There is still uncertainty as to 
whether the susceptibility is due to the older age group in which PCa is most prominent and the 
likelihood that pre-existing conditions become more pronounced with ADT related metabolic 
abnormalities [41]. Ongoing research specifically designed to capture the effects of different ADT 
drugs on CV risk may provide further clarity in this controversial area [41, 42].  
 
ADT has the propensity to accelerate the loss of bone mineral density (BMD), which has significant 
implications for osteoporosis and is a surrogate marker for fracture risk within the ageing PCa 
population [26]. There tends to be a higher rate of bone loss earlier in the treatment trajectory, but 
this steadily decreases over time. The areas incurring the greatest degree of bone loss include lumbar 
vertebrae (-3.6%), femoral neck (-3.11%) and total hip area (-1.59%) [43]. Observational studies have 
yielded fairly consistent results regarding fracture risk with a recent retrospective study capturing a 
39% increase in overall risk, which continued to rise with ADT duration [44]. Fractures are an 
important consideration for men with PCa on ADT as they can be associated with reduced QoL and 
are also an independent predictor of decreased overall survival [26, 29].  
 
RT 
Patients on ADT who are also undergoing RT often have to contend with additional acute or late 
toxicities, particularly those that arise from the dose-limiting organs at risk (OAR) falling within the 
radiation field, including the bilateral femoral heads, the bladder and rectum [45]. Although 
technological advances in RT techniques are protective factors for these vulnerable structures, there 
is still the occurrence of daily treatment uncertainties such as set up errors, variation in the size and 
shape of the prostate, changes in bladder and rectum volumes and inter/intrafraction motion of the 
prostatic bed [46, 47].  
 
There is a dearth of literature pertaining to RT induced hip-related complications. While this toxicity 
is less common, it is an important consideration with newer treatment plans employing higher 
radiation doses, especially for those using ADT who are already at an increased risk of osteoporotic 
changes [48]. Elliot et al [49] reported an increased risk of 76% for hip fractures associated with RT 
and a further increase for those on combined treatment, without increasing the risk of fragility 
fractures in bones outside of the radiation area (distal forearm). However, Zelefksy et al [48] suggests 
the risk is negligible with appropriate planning and application of dose constraints to the femoral 
heads, therefore it is only those with pre-existing degenerative joint disorders or prolonged ADT 
exposure that may be at increased risk. 
 
The most investigated radiation dose-volume relationships focus on genitourinary (GU) and 
gastrointestinal (GI) toxicities, noting that the risk factors vary for each individual patient based on 
their unique clinical and personal profiles [50]. When comparing combined treatment with ADT as a 
monotherapy, the evidence consistently reflects that both GU and GI side effects are transient in 
nature with little clinically or statistically significant difference in symptom scores at long term 
follow-up [51]. Warde et al [52] noted that the adverse effects in the combined treatment group 
were clinically modest and short-lived, with Grade 1 and Grade 2 GI toxicities, see Table 3, 
(manageable diarrhoea and rectal bleeding) evident at 6 months but noted recovery by 36 months. 
GU scores were already elevated at baseline due to disease related symptoms. Mason et al [32] 
reiterated that toxicities were more pronounced for combined treatment initially with urinary 
frequency recorded at 7% for ADT/RT compared to 4% for ADT alone. Once again, severe GI events 
were negligible at a 24 month follow up. Sargos et al [53] reported that ≥ Grade 2 GU and GI 
toxicities were more frequent in the combined arm compared with ADT alone (GI = 17% vs 1% and 
GU = 12% vs 1%) however, after 6 months these gradually decreased throughout the follow-up 
period. With radiation centres implementing strict bladder and bowel preparation protocols, the 
advances in radiation technology and inclusion of image guided RT, the radiation dose to the 
prostate can be delivered with a high level of conformality, in turn reducing the dose received by the 
OAR and surrounding tissues, while still achieving superior biochemical control [54, 55]. 
 
Nursing Implications 
It is important for nurses to understand the Four Rs of Radiobiology (Repair, Reoxygenation, 
Reassortment and Repopulation) to understand the effects of ionising radiation on biological tissue 
and subsequently as the basis for conventional fractionated treatment schedules.  An important 
aspect of nursing of men receiving RT (+/- ADT) is the provision of care, support and self-
management advice [56].  Men can experience a range of unmet supportive care needs particularly 
related to informational, sexual and psychological needs [57]. For men affected by PCa opting for RT 
nurses should ask targeted questions based on the Common Terminology Criteria for Adverse Events 
(CTCAE) related to urinary and bowel function, potency and fatigue and sexual health [58].  We also 
recommend the routine use of holistic needs assessments to tailor self-management care plans [59]. 
Evidence-based self-management advice should be provided in response to each man’s unique needs 
[60]. Nurses providing care to men requires expert technical knowledge and advanced 
communication skills.  Care provision must reflect evidence-based clinical guidelines and care 




It is important for nurses to understand the Four Rs of Radiobiology to grasp the effects of ionising 
radiation on biological tissue as the basis for conventional fractionated treatment schedules in PCa. 
Men can experience a sequalae of physical and psychological side-effects of treatment which can 
negatively impact quality of life.  Nurses can provide expert technical knowledge with advanced 
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Table 1: Clinical Tumour Node Metastasis (TNM) classification of PCa [61] 
 
T - Primary Tumour (stage based on digital rectal examination [DRE] only) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour that is not palpable 
 
T1a Tumour incidental histological finding in 5% or less of tissue resected 
 
T1b Tumour incidental histological finding in more than 5% of tissue resected 
 
T1c Tumour identified by needle biopsy (e.g. because of elevated prostate-specific antigen [PSA]) 
T2 Tumour that is palpable and confined within the prostate 
 
T2a Tumour involves one half of one lobe or less 
 
T2b Tumour involves more than half of one lobe, but not both lobes 
 
T2c Tumour involves both lobes 
T3 Tumour extends through the prostatic capsule 
 
T3a Extracapsular extension (unilateral or bilateral) 
 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: external sphincter, rectum, 
levator muscles, and/or pelvic wall 
N - Regional (pelvic) Lymph Nodes1 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M - Distant Metastasis2 
M0 No distant metastasis 
M1 Distant metastasis 
 




M1c Other site(s) 
1 Metastasis no larger than 0.2 cm can be designated pNmi. 
2 When more than one site of metastasis is present, the most advanced category is used. (p)M1c is the most 
advanced category. 




Low-risk Intermediate-risk High-risk 
PSA < 10 ng/mL PSA 10-20 ng/mL PSA > 20 ng/mL any PSA 
and GS < 7 (ISUP grade 1) or GS 7 (ISUP grade 2/3) or GS > 7 (ISUP grade 4/5) any GS (any ISUP grade) 
and cT1-2a or cT2b or cT2c cT3-4 or cN+ 
Localised Locally advanced 





Table 3a: RTOG ACUTE Radiation Morbidity [62] 
 
Tissue Grade 1 Grade 2 Grade 3 Grade 4 
Lower GI / Pelvis Increased frequency or change 
in quality of bowel habits not 
requiring medication / rectal 
discomfort not requiring 
analgesics. 
Diarrhoea requiring 
parasympatholytic drugs (e.g. 
Lomotil) / mucous discharge not 
necessitating sanitary pads / 
rectal or abdominal pain 
requiring analgesics. 
Diarrhoea requiring parenteral 
support / severe mucous or 
blood discharge necessitating 
sanitary pads / abdominal 
distention (flat plate radiograph 
demonstrates distended bowel 
loops). 
Diarrhoea requiring parenteral 
support / severe mucous or 
blood discharge necessitating 
sanitary pads / abdominal 
distention (flat plate radiograph 
demonstrates distended bowel 
loops). 
 
Genitourinary (GU) Frequency of urination or 
nocturia twice pre-treatment 
habit / dysuria, urgency not 
requiring medication. 
Frequency of urination or 
nocturia that is less frequent 
than every hour. Dysuria, 
urgency, bladder spasm 
requiring local anaesthetic (e.g. 
Pyridium). 
Frequency with urgency and 
nocturia hourly or more 
frequently / dysuria, pelvis pain 
or bladder spasm requiring 
regular, frequent narcotic / 
gross haematuria 
with/without clot passage. 
 
Haematuria requiring 
transfusion / acute bladder 
obstruction not secondary to 
clot passage, ulceration, or 
necrosis. 
For all: 0 – no symptoms, 5 – death directly related to radiation effects 
 
Table 3b: RTOG/EORTC LATE Radiation Morbidity [62] 
 
Tissue Grade 1 Grade 2 Grade 3 Grade 4 
Small/Large Intestine Mild diarrhoea; mild cramping; 
bowel movement 5 times daily; 
slight rectal discharge or 
bleeding. 
Moderate diarrhoea and colic; 
bowel movement > 5 times 
daily; excessive rectal mucus or 
intermittent bleeding. 
 
Obstruction or bleeding, 
requiring surgery. 
Necrosis / perforation fistula. 







Severe frequency & dysuria; 
severe telangiectasia (often 
with petechiae); frequent 
haematuria; reduction in 
bladder capacity (<150 cc). 
 
Necrosis/contracted bladder 
(capacity < 100 cc); severe 
haemorrhagic cystitis. 
For all: 0 – no symptoms, 5 – death directly related to radiation effects 
 
